What the internist should know about stem cell transplant in the elderly patient.
Most hematological malignancies are increasing in frequency with age. Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapeutic option for patients with malignant and non-malignant hematological diseases. The treatment of elderly patients with advanced hematological malignancies has expanded to include reduced intensity conditioning allo-HCT. Physicians increasingly refer older patients for allo-HCT due to more experience and improved supportive care in allo-HCT. This review article discusses the available data regarding the feasibility, tolerability, toxicity, and effectiveness of allo-HCT in different hematological diseases in the elderly. Over the past decade, utilization and survival after allo-HCT have increased in patients ≥70 years. Selected adults ≥70 years with hematological diseases should be evaluated for transplantation.
['Medinger|Michael|M|', 'Passweg|Jakob|J|']
D000368:Aged D015897:Comorbidity D015577:Geriatric Assessment D019337:Hematologic Neoplasms D018380:Hematopoietic Stem Cell Transplantation D006801:Humans D007167:Immunotherapy D019172:Transplantation Conditioning D014184:Transplantation, Homologous
Elderly patients Conditioning regimen Donor choice Geriatric assessment Hematopoietic stem cell transplantation